AcuTect Phase IV Study Will Examine Utility Of Negative Thrombosis Scans
This article was originally published in The Gray Sheet
The clinical utility of a negative test result in the imaging of venous thrombosis will be examined in a post-approval study of Diatide's AcuTect. The apcitide technetium Tc 99m kit was approved by FDA Sept. 14.
You may also be interested in...
Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.